diclofenac and eflornithine

diclofenac has been researched along with eflornithine in 8 studies

Research

Studies (8)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (12.50)	29.6817
2010's	7 (87.50)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Ahlin, G; Artursson, P; Bergström, CA; Gustavsson, L; Karlsson, J; Larsson, R; Matsson, P; Norinder, U; Pedersen, JM	1
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A	1
Bellera, CL; Bruno-Blanch, LE; Castro, EA; Duchowicz, PR; Goodarzi, M; Ortiz, EV; Pesce, G; Talevi, A	1
Burcharth, J; Pommergaard, HC; Raskov, H; Rosenberg, J	3
Afaq, F; Arumugam, A; Athar, M; Chaudhary, SC; Elmets, CA; Kopelovich, L; Talwelkar, SS; Weng, Z	1
Alberts, DS; Bartels, HG; Bartels, P; Bermudez, Y; Curiel-Lewandrowski, C; Einspahr, JG; Hu, C; Jeter, JM; Myrdal, PB; Stratton, SP; Warneke, JA; Yozwiak, M	1

Trials

1 trial(s) available for diclofenac and eflornithine

Article	Year
Phase IIB Randomized Study of Topical Difluoromethylornithine and Topical Diclofenac on Sun-Damaged Skin of the Forearm. Cancer prevention research (Philadelphia, Pa.), 2016, Volume: 9, Issue:2 Topics: Administration, Topical; Adult; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Diclofenac; Eflornithine; Female; Follow-Up Studies; Forearm; Humans; Keratosis, Actinic; Male; Middle Aged; Prognosis; Skin; Skin Neoplasms; Sunlight	2016

Article

Year

Phase IIB Randomized Study of Topical Difluoromethylornithine and Topical Diclofenac on Sun-Damaged Skin of the Forearm.

Cancer prevention research (Philadelphia, Pa.), 2016, Volume: 9, Issue:2

Topics: Administration, Topical; Adult; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Diclofenac; Eflornithine; Female; Follow-Up Studies; Forearm; Humans; Keratosis, Actinic; Male; Middle Aged; Prognosis; Skin; Skin Neoplasms; Sunlight

2016

Other Studies

7 other study(ies) available for diclofenac and eflornithine

Article	Year
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1. Journal of medicinal chemistry, 2008, Oct-09, Volume: 51, Issue:19 Topics: Cell Line; Computer Simulation; Drug Design; Gene Expression Profiling; Humans; Hydrogen Bonding; Liver; Molecular Weight; Organic Cation Transporter 1; Pharmaceutical Preparations; Predictive Value of Tests; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Structure-Activity Relationship	2008
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species. Chemical research in toxicology, 2010, Volume: 23, Issue:1 Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship	2010
Prediction of drug intestinal absorption by new linear and non-linear QSPR. European journal of medicinal chemistry, 2011, Volume: 46, Issue:1 Topics: Humans; Intestinal Absorption; Linear Models; Molecular Conformation; Nonlinear Dynamics; Permeability; Pharmaceutical Preparations; Probability; Quantitative Structure-Activity Relationship; Thermodynamics	2011
Topical treatment with diclofenac, calcipotriol (vitamin-D3 analog) and difluoromethylornithine (DFMO) does not prevent nonmelanoma skin cancer in mice. Cancer investigation, 2013, Volume: 31, Issue:2 Topics: Administration, Topical; Animals; Anticarcinogenic Agents; Antineoplastic Agents; Calcitriol; Diclofenac; Eflornithine; Female; Mice; Mice, Hairless; Random Allocation; Skin Neoplasms	2013
Combination chemoprevention with diclofenac, calcipotriol and difluoromethylornithine inhibits development of non-melanoma skin cancer in mice. Anticancer research, 2013, Volume: 33, Issue:8 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Calcitriol; Chemoprevention; Diclofenac; Eflornithine; Female; Melanoma; Mice; Precancerous Conditions; Skin Neoplasms; Survival Analysis	2013
Topical combination of diclofenac, calcipotriol, and difluoromethylornithine has beneficial effects comparable to 5-fluorouracil for the treatment of non-melanoma skin cancer in mice. Journal of chemotherapy (Florence, Italy), 2014, Volume: 26, Issue:2 Topics: Administration, Topical; Animals; Antineoplastic Combined Chemotherapy Protocols; Calcitriol; Diclofenac; Eflornithine; Female; Fluorouracil; Mice; Mice, Hairless; Random Allocation; Skin Neoplasms	2014
Inhibiting cycloxygenase and ornithine decarboxylase by diclofenac and alpha-difluoromethylornithine blocks cutaneous SCCs by targeting Akt-ERK axis. PloS one, 2013, Volume: 8, Issue:11 Topics: Animals; Carcinoma, Squamous Cell; Carrier Proteins; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Diclofenac; Down-Regulation; Eflornithine; Female; Humans; MAP Kinase Signaling System; Mice; Mice, Nude; Ornithine Decarboxylase; Ornithine Decarboxylase Inhibitors; Phosphorylation; Proto-Oncogene Proteins c-akt; Signal Transduction; Skin Neoplasms	2013